Banking

Teva Earnings Top But Drugmaker’s Sales Just Miss Views

Teva Pharmaceutical (TEVA) reported a fourth quarter of lackluster sales on Wednesday, leading Teva stock to dive for the second straight day.




X



For the first quarter ended March 31, the generic drugs behemoth reported $3.98 billion in sales. Sales declined 9% and just missed the forecast of analysts polled by FactSet for $4.02 billion. This was the fourth period in which sales either declined or were flat.

Adjusted earnings also toppled 17% to 63 cents per share. But that beat bearish forecasts from Teva stock analysts for 59 cents per share.

On today’s stock market, Teva stock skidded 2.4% to 10.12.

Teva Stock Dips On Lagging Sales

Sales in North America slipped 5% to $1.99 billion.

Teva blamed lower sales from its Anda unit, a generic drug business acquired from Allergan, multiple sclerosis treatment Copaxone and cancer medicines Bendeka and Treanda. Other generic drugs and Austedo, a treatment for involuntary movements, helped partially offset those declines.

“Our North America segment has experienced some reductions in volume due to less physician and hospital activity during the Covid-19 pandemic, but has also experienced increase in demand for certain products related to the treatment of Covid-19 and its symptoms,” Teva said in a news release.

Europe, International Sales Fall

Revenue in Europe and internationally declined 13% each.

Overall, sales of generic drugs ticked down 5% to $2.31 billion. Generic drug sales climbed 11% in the North America business, but fell in Europe and abroad. Another sore point for Teva stock: Its biggest single drug, Copaxone, generated $276 million, falling 16%.

Teva reaffirmed its outlook for 2021. The company calls for $16.4 billion to $16.8 billion in sales and adjusted profit of $2.50-$2.70 per share. Teva stock analysts called for profit of $2.62 a share and $16.7 billion in sales.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

Novartis Generics Face ‘Challenging Quarter,’ But Gene Therapy Shines

Eli Lilly Stock Crumbles As Covid Antibodies Hammer Sales, 2021 Outlook

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

Get Stock Ideas From IBD Experts Each Morning Before The Open

Watch IBD’s Investing Strategies Show For Actionable Market Insights


Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button